Navigation Links
TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
Date:3/18/2008

icans," said Steven Taylor, Chief Executive Officer of the Sjogren's Syndrome Foundation. "While there are treatments available for xerostomia, there is still a significant need for new therapies that could offer patients less frequent dosing regimens and better tolerability."

About Xerostomia

Xerostomia, or dry mouth, is the result of decreased salivary flow and is a symptom of a number of underlying conditions. Causes of dry mouth include Sjogren's syndrome; radiation treatment to the head and neck; and HIV-related salivary gland disease. Xerostomia can also be a side effect of medications and is associated with aging.

About TorreyPines Therapeutics

TorreyPines Therapeutics is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions, including statements regarding the company's strategic plan for 2008, the versatility of the company's product candidates, the potential of NGX267 as a treatment for xerostomia and the potential timing and scope of clinical trials of NGX267. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
2. TorreyPines Therapeutics Reports Third Quarter 2007 Results
3. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
6. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
9. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
10. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
11. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... MediVet America and NanoFiber Veterinary ... at the specialized Wolvega Horse Clinic. , Due to ... was ruptured 90% and her deep digital flexor tendon ... sentence for a horse. , The clinic has performed ... This revolutionary regenerative option for ruptured tendons has ...
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... , Sept. 19, 2014  Nektar Therapeutics ... from preclinical studies characterizing the analgesic profiles of ... kappa opioid receptor agonist molecules. The preclinical research ... medicinal chemistry platform. The analgesic properties ... the medical literature. 1,2 Kappa opioid receptors ...
(Date:9/19/2014)... Minnesota (PRWEB) September 19, 2014 ... related food industries will gather October 5–8, 2014, ... the Rhode Island Convention Center in Providence, Rhode ... feature the work of food scientists, chemists, microbiologists, ... control, and food production management. To date, 1,000 ...
Breaking Biology Technology:World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3Toward optical chips 2Toward optical chips 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 2Latest Research on Cereal Grain Quality, Health Benefits and Food Production to be Presented During the AACC International Annual Meeting 3
... of technologies showcased at the American Society for, Therapeutic Radiology and ... ... 2008, BOSTON, Sept. 22 ASTRO Booth # 547 -- Varian,Medical ... cancer and other disorders, is showcasing a full,spectrum of technologies and products ...
... Delivery Enable CyberKnife Centers ... Increasing Demand for Radiosurgery, SUNNYVALE, Calif., Sept. 22 ... in the field of radiosurgery,announced today that Oklahoma CyberKnife ... dramatically reduced treatment,planning and delivery times over the last ...
... from Varian Medical Systems and BrainLAB enabling, non-invasive treatment of ... ... system, PALO ALTO, Calif., and WESTCHESTER, Ill., Sept. ... of stereotactic body radiosurgery (SBRT) for the treatment,of cancer and other conditions. ...
Cached Biology Technology:Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 2Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 3Varian Medical Systems Exhibits a New Version of RapidArc(TM) Radiotherapy Technology and Other Products for Fast, Precise Cancer Treatment 4Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 2Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 3Oklahoma CyberKnife Center Cuts Treatment Time in Half With Next Generation CyberKnife Technology 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 2Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 3Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 4Non-Invasive Radiosurgery with Novalis Tx(TM) Platform Rolling Out Worldwide 5
(Date:9/18/2014)... its newborn screening program into a model other states can ... first-ever Newborn Screening Quality Award from the March of Dimes. ... Arizona,s Department of Health Services director, with the award at ... of full transparency for the length of time it takes ... for analysis, and set a target of having 95 percent ...
(Date:9/18/2014)... disciplines will be celebrated tonight at the third annual ... the health of premature infants and in paving the ... whose work was supported by the National Science Foundation, ... Energy Commission, will be honored at a ceremony at ... group of Members of Congress will be on hand ...
(Date:9/18/2014)... 2014 Elsevier, a world-leading provider of scientific, ... the Australasian Research Management Society (ARMS), recognized the ... the 5th Scopus Young Researcher of the Year ... at the National Convention Centre and in conjunction ... by guests representing Australia,s and New Zealand,s scientific ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... and Women,s Hospital (BWH) announces the launch of the ... division within the Department of Medicine. The Channing Division ... biology-driven approach to define the causes of complex diseases. ... develop new ways to classify and treat those diseases. ...
... of Health have developed a new silk-based stabilizer that, ... up to temperatures of 140 degrees Fahrenheit. ... to keep some vaccines and antibiotics refrigerated, which could ... to third world populations. Vaccines and antibiotics often ...
... When coronary blood vessels are constricted, cardiologists try to ... grid-like implants called stents, which stabilize the veins and ... obliteration. A lesser known fact is that stents can ... This kind of respiratory stenosis, which may be caused ...
Cached Biology News:BWH launches a new research division focused on integrating systems biology and medicine 2Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study 2Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study 3Non-slip tracheal implants 2
Active GST Protein...
... Cyno Serum • Cyno serum is collected off ... and 5-7 years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: Potassium ... Alsevers N-05: ACD N-07: CPD ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
adult...
Biology Products: